Skyline Medical Issues Letter to Shareholders, Ticker: SKLNY

Skyline Medical Inc.

today issued the following letter to shareholders: Dear Fellow Shareholders, Skyline Medical has never been in a stronger position for long-term success. Given recent commercial accomplishments, as well as the enhanced capital position of the company and our NASDAQ listing, we want to take this opportunity to highlight our plans to drive future growth. Thus far in 2015, with limited sales personnel, we have signed numerous agreements with major hospitals. In total, there are 90 STREAMWAY(R) Systems installed in 45 hospitals and surgery centers in 19 states across the U.S., including the recent addition of several larger hospitals, teaching hospitals and surgical centers, such as Duke University Health System, Beth Israel Deaconess Medical Center (a Harvard Medical School Affiliate), Dartmouth-Hitchcock Medical Center, Penn State Milton S. Hershey Medical Center and Oscar G. Johnson VA Medical Center. We believe the early adoption of our product by such esteemed institutions further highlights our product as the best for its application. We believe there continues to be a significant opportunity for our product to be adopted by new and existing hospitals across their operating rooms. Currently, there are more than 40,000 operating rooms in the U.S., in which over 80 million procedures are performed each year. With a trial-to-sale conversion rate of 98%, the STREAMWAY System has validated itself in the market. We strengthened our balance sheet in August with the successful completion of a capital raise concurrently listing on the NASDAQ. This new injection of cash, combined with a business model that generates recurring revenues from ancillary products used with each unit deployed has greatly strengthened our ability to support the implementation of our growth strategy. In order to further penetrate the market, we are in the process of implementing an aggressive sales and marketing strategy for our STREAMWAY Systems, including the establishment of a dedicated salesforce throughout the U.S. We are looking to broaden market awareness of our product by selling to existing customers, new customers, new construction, GPOs, large surgery center chains and federal government contracts. We are also pursuing the regulatory pathway and distribution strategy intended to lead to global expansion. As an innovative product, the STREAMWAY System offers significant safety, economic and environmental benefits to our customers. The STREAMWAY is the only product in the market that offers continuous suction and flow with the ability to measure fluid waste, offering significant advantages to hospital staff. The innovative, direct-to-drain design offers a broad array of benefits, including eliminating staff exposure to harmful fluids, reducing costs for the hospital, and simplifying the entire fluid waste disposal process. There is no other product in the market with this functionality, and as such, we believe that our product will revolutionize the way that hospitals and medical centers dispose of hazardous waste. Investments are also being made in Research and Development to create enhancements for existing products, as well as the possible creation of new and complementary products to grow our revenue. We are proud of our achievements in 2015 and excited about the long-term potential for the business. We have a state-of-the-art offering for a growing segment of the surgical equipment market and believe there are significant growth opportunities ahead. We thank you for your investment and continued support during this period and look forward to keeping all of our shareholders apprised of our continued progress.